We read with interest the recent article in which Trifilio et al. 1 reported the results of preemptive dose modification and therapeutic drug monitoring of tacrolimus in recipients of allogeneic hematopoietic SCT receiving both tacrolimus and voriconazole. They showed that their preemptive dose modification succeeded in maintaining the blood concentration of tacrolimus in spite of the significant drug interaction between tacrolimus and voriconazole. Although we partly agree with their results and opinions, we would like to make several comments.
Our previous report, 2 which was cited in theirs, showed that voriconazole administration significantly increased the blood concentration of calcineurin inhibitors such as tacrolimus and CsA with significant interindividual variability. We used a concentration/dose (C/D) ratio ((ng/mL)/ (mg/kg)) for the quantitative evaluation of the drug interaction, and the median increase in the C/D ratio of tacrolimus after voriconazole administration was 115.6%, with a range of 25.4À307.6%. Thus, we concluded that dose adjustment of calcineurin inhibitors (tacrolimus and CsA) should be made on an individual basis, although the manufacturer's recommendation sets uniform dose-reduction rates (1/3 of the original dose for tacrolimus, 1/2 for CsA). 3 We believe that there are two prominent differences between the report of Trifilio et al. and ours. One is the method of evaluating the drug interaction. The authors used dose-reduction rates for evaluation, which could not quantitatively evaluate the exact drug interaction, because their method focused solely on the dose of tacrolimus while the target concentration has a wide range among patients (5-20 ng/mL). In contrast, we used the C/D ratio ((ng/mL)/ (mg/kg)) for the quantitative evaluation of drug interaction, which reflects both the concentration and dose of calcineurin inhibitors. We believe that the results using this method could provide more meaningful data with clinical relevance. The other difference is in the timing of evaluation of the drug interaction. In our study, the effect of voriconazole administration was evaluated 7-10 days after initiating voriconazole in patients who were on a steady dose of calcineurin inhibitors. Thus, it was possible to determine the true effect of voriconazole administration on tacrolimus concentration. In contrast, in the Trifilio study, tacrolimus was initiated on day 1 and voriconazole on day 0. In such an instance, the drug interaction would be extensively affected by the as-yet-unstabilized pharmacokinetics of both tacrolimus and voriconazole. For the quantitative evaluation of drug interactions, the drug concentration of at least one of the two drugs should be stabilized. Voriconazole was initiated on day 0 according to their hospital protocol; however, voriconazole should have been initiated earlier (i.e. 7-10 days before initiating tacrolimus) so that tacrolimus could be initiated when the blood concentration of voriconazole had stabilized. This would have simplified the protocol to target the drug interaction specifically.
The authors' interpretation of their results was different from ours. However, we believe that the results themselves were almost identical. First, the authors asserted that a preemptive dose-reduction strategy was not used in our study. This is not entirely true as the tacrolimus dose used in our study was adjusted according to the blood concentration of tacrolimus measured every 1-2 days as described. Although reduction rates were determined by each physician, the dose of tacrolimus was reduced immediately after the concentration of tacrolimus increased: in other words, preemptively. Second, we believe that the wide interindividual variability of the drug interaction shown in our study is quite similar to that observed in the authors' report, which showed a wide range in the median dose standardized by weight on both day 7 (0.018-0.025 mg/kg) and day 14 (0.004-0.017 mg/kg).
In addition, the initial dose of tacrolimus was 0.02 mg/kg in the authors' study, which is a 30% reduction from the recommended dose (0.03 mg/kg). Our observation of wide interindividual variability suggests that a uniform dose reduction to one-third of the original dose recommended by the manufacturer is not optimal, as it would result in a subtherapeutic concentration of tacrolimus in some patients. Thus, we agree with not using one-third as the dosereduction rate of tacrolimus. However, according to the authors, this dose setting is consistent with the current product guidelines for reduction of tacrolimus dose when administered concomitantly with voriconazole, in which the manufacturer recommends reducing the dose of tacrolimus to one-third of the original dose, which would be 0.01 mg/kg.
In conclusion, although the design and methods used in the two studies are different, we believe that they share the same clinically important observation. The dose of tacrolimus should be adjusted on an individual basis according to a careful and close monitoring of its concentration in patients receiving voriconazole, with the aim of minimizing its dose-related toxicity and maximizing its immunosuppressive effects.
